Eosinophil-degranulation products drive a proinflammatory fibroblast phenotype - 05/10/18
Doi : 10.1016/j.jaci.2018.05.037
Ksenija Bernau, PhD a, Jonathan P. Leet, BS a, Stephane Esnault, PhD a, Andrea L. Noll, BS a, Michael D. Evans, MS b, Nizar N. Jarjour, MD a, Nathan Sandbo, MD a 
a Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wis
b Biostatistics and Medical Informatics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wis
| Funding for this research was provided by the National Institutes of Health (grant no. NIH HL088594 to N.N.J. and grant no. NIH HL136795 to N.S.), University of Wisconsin-Madison, Department of Medicine Pilot Funding (N.S.), and American Heart Association Postdoctoral Fellowship (16POST26690001 to K.B.). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2018
Publié par Elsevier Masson SAS.
Vol 142 - N° 4
P. 1360 - octobre 2018 Retour au numéro
Article précédent
- Questioning the accuracy of currently available pneumococcal antibody testing
- Joud Hajjar, Aba Al-Kaabi, Carleigh Kutac, James Dunn, William T. Shearer, Jordan S. Orange
- Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2
- Pui Y. Lee, Yuelong Huang, Qing Zhou, Oskar Schnappauf, Michael S. Hershfield, Ying Li, Nancy J. Ganson, Natalia Sampaio Moura, Ottavia M. Delmonte, Scellig S. Stone, Michael J. Rivkin, Sung-Yun Pai, Todd Lyons, Robert P. Sundel, Victor W. Hsu, Luigi D. Notarangelo, Ivona Aksentijevich, Peter A. Nigrovic
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?